City Therapeutics, Inc. (CTY)

Profile

https://www.citytx.com

City Therapeutics, Inc. is a clinical-stage biotechnology company developing RNA interference therapeutics that selectively silence the expression of disease-relevant proteins. Its platform is designed to address biological targets that may be difficult to modulate with conventional medicines, with an emphasis on creating durable effects through precisely engineered RNAi molecules and delivery technologies. The company’s pipeline includes CITY-FXI, an early-stage clinical candidate focused on Factor XI, a protein involved in blood coagulation, alongside additional development programs targeting medically significant diseases. City Therapeutics operates within the biopharmaceutical sector, combining molecular biology, drug delivery, translational research, and clinical development. Its work supports the broader application of RNA-based medicines across therapeutic areas where reducing production of a specific protein could offer a targeted treatment approach. As a clinical-stage biotechnology enterprise, City Therapeutics contributes to the development of innovative pharmaceutical products rather than marketed commercial therapies, serving the research, healthcare, and life sciences markets.